Overview

A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Status:
Enrolling by invitation

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Brivaracetam